Infliximab | Etanercept | Adalimumab | |
---|---|---|---|
Structure | Chimeric mAb | TNF IgG1 | Human mAb |
Fusion protein | |||
Binding target | TNF | TNF, lymphotoxin | TNF |
Binding affinity | 1.8×109 | 1010 | 2.3×1010 |
Half life (days) | 8–9.5 | 4–5 | 12–14 |
In vitro cell lysis | + | − | + |
Dose | Every 60 days | Every 3–4 days | Every 7–14 days |
Efficacy/Crohn’s disease | + | − | ? |